v3.24.1.u1
Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total revenues from anti-CD20 therapeutic programs $ 2,290.5 $ 2,463.0
Genentech    
Disaggregation of Revenue [Line Items]    
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA 87.1 112.5
Other revenues from anti-CD20 therapeutic programs 4.2 3.4
Revenue from anti-CD20 therapeutic programs    
Disaggregation of Revenue [Line Items]    
Total revenues from anti-CD20 therapeutic programs 394.0 399.5
Royalty Attributed To OCREVUS    
Disaggregation of Revenue [Line Items]    
Total revenues from anti-CD20 therapeutic programs $ 302.7 $ 283.6